Matinas BioPharma Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Matinas BioPharma Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $119.8K | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $149.7K | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $0 | Mar 31, 2017 |
| FY2017 | Dec 31, 2015 | $194.5K | Mar 16, 2018 |
| FY2015 | Dec 31, 2014 | $0 | Mar 30, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $1.10M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $3.19M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $33.0K | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $158.3K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $89.8K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $119.8K | Mar 9, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.35M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($24.25M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($22.94M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($21.00M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($23.28M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($22.45M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($17.37M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($14.08M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($15.49M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($7.60M) | Mar 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.96M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($24.59M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($23.77M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($24.59M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($24.74M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($24.21M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($18.92M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($14.65M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($16.50M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($8.26M) | Mar 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.43M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $14.49M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $16.68M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $14.58M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $14.36M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $11.23M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $6.79M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $9.01M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.95M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.01M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($15.89M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($15.28M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($19.16M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($15.22M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($17.37M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($14.09M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($10.32M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($11.46M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($6.12M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $218.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $892.0K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $260.0K | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $5.7K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $405.6K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $535.9K | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $942.2K | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $0 | Mar 31, 2017 |
| FY2017 | Dec 31, 2015 | $76.2K | Mar 16, 2018 |
| FY2015 | Dec 31, 2014 | $288.5K | Mar 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.21M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.64M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $25.10M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $44.82M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $61.33M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $70.97M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $40.24M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $19.94M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $14.42M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.82M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.05M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.86M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $8.18M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $8.83M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $7.24M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $7.19M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $3.80M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $3.74M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.67M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.83M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.59M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $19.25M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $36.64M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $52.49M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $63.73M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $33.05M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $16.14M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $10.68M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $7.15M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2023 | $1.34M | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $1.34M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.34M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.34M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.34M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.34M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $1.34M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.34M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.34M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 30, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($210.79M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($199.82M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($175.57M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($152.63M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($131.63M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($107.51M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($84.38M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($65.94M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($51.27M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($35.18M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.00M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.28M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $4.79M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $6.83M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $21.03M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $12.43M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $22.17M | Mar 11, 2022 |
| FY2019 | Dec 31, 2018 | $12.45M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $7.31M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.11M | Mar 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.41M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 5.09M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 4.35M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 217.26M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 216.27M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 200.11M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 163.16M | Mar 29, 2021 |
| FY2019 | Jun 19, 2019 | 946,000 | Mar 9, 2020 |
| FY2019 | Dec 31, 2018 | 113.29M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 93.37M | Apr 1, 2019 |